Key result
A 1-month course of azithromycin was well tolerated but demonstrated no effect on anti-Chlamydia pneumoniae antibody titres at 6 months in adults with coronary artery disease.
Why the study?
Does a 1-month course of azithromycin improve anti-Chlamydia pneumoniae antibody titres or safety in adults following percutaneous coronary revascularization?
Population
Adults with coronary artery disease following percutaneous coronary revascularization procedures
Comparison
Azithromycin for 1 month (total dose of 8.0 g) vs Placebo
Design
RCT, randomized
Follow-up
6 months
Authors
Loading...
Azithromycin is safe but ineffective at reducing anti-C. pneumoniae titres post-PCI; challenges serological benefit hypothesis in CAD.
RCT
randomized
Does a 1-month course of azithromycin improve anti-Chlamydia pneumoniae antibody titres or safety in adults following percutaneous coronary revascularization?
A 1-month course of azithromycin following percutaneous coronary revascularization was safe but did not reduce anti-Chlamydia pneumoniae antibody titers at 6 months.
Jackson et al. (1999) conducted an RCT in Coronary artery disease. Azithromycin vs. Placebo was evaluated on Safety and anti-Chlamydia pneumoniae antibody titres. A 1-month course of azithromycin was well tolerated but demonstrated no effect on anti-Chlamydia pneumoniae antibody titres at 6 months in adults with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: